Stay updated on Pembrolizumab Combo in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page
- Check6 days agoChange DetectedAdded related topics: Lung cancer and MedlinePlus Genetics to the page to link to broader information.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check21 days agoChange DetectedThe study's locations section was expanded to include new sites across multiple countries and states, and several prior location entries were removed. A revision tag (Revision: v3.3.3) is also noted on the page.SummaryDifference2%

- Check28 days agoNo Change Detected
- Check50 days agoChange DetectedLung cancer and related topics (MedlinePlus Genetics) were added and the Publications note now states that publications are automatically filled from PubMed, with the revision tag updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check57 days agoChange DetectedThe government funding notice at the bottom of the page has been removed. The study details and overall content remain unchanged.SummaryDifference0.2%

- Check64 days agoChange Detected- The related topics section no longer lists Lung cancer and MedlinePlus Genetics. This is a minor navigational/metadata change that does not affect the study content.SummaryDifference0.1%

- Check71 days agoChange DetectedNo significant changes were detected in core study details; observed updates seem limited to formatting or UI adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Combo in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.